Search people, articles, bills, and more
This bill matters because it addresses a common complaint among seniors: that their drug costs don't reflect the true cost of medicine after the deep discounts and rebates insurance companies receive. By requiring cost-sharing for chronic care drugs to be based on the 'net price'—the price after manufacturer discounts—it could lead to significant savings for millions of Americans who manage ongoing health conditions.
If this bill becomes law, voters, especially those on Medicare Part D, could see lower out-of-pocket costs for essential, life-sustaining medications starting in 2027. Without this bill, patients would continue to pay cost-sharing amounts that might be based on higher, pre-discount prices, meaning they could pay more than necessary for their chronic care drugs.
No reactions yet. Be the first to weigh in.
This bill matters because it addresses a common complaint among seniors: that their drug costs don't reflect the true cost of medicine after the deep discounts and rebates insurance companies receive. By requiring cost-sharing for chronic care drugs to be based on the 'net price'—the price after manufacturer discounts—it could lead to significant savings for millions of Americans who manage ongoing health conditions.
If this bill becomes law, voters, especially those on Medicare Part D, could see lower out-of-pocket costs for essential, life-sustaining medications starting in 2027. Without this bill, patients would continue to pay cost-sharing amounts that might be based on higher, pre-discount prices, meaning they could pay more than necessary for their chronic care drugs.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)